| Followers | 59 |
| Posts | 7593 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Tuesday, December 10, 2024 8:23:03 AM
Sadly, the biotech world is corrupt and these BOD
members will always find ways to benefit from situations
even if technically it may be illegal to do so, they will find
a way. My speculation is that Tang "knows" that AUPH
will be acquired by BP at a time and a price that will enrich
himself and the other board members. Even PG made a
comment at the conclusion of the strategic review that at
anytime a BP can make an offer for AUPH, even though
the strategic review process had ended. Maybe PG set
the bar to high for an official offer to be made at that time.
As of right now, it looks as if AUPH is more attractive than
it was in the past. Tang knows how the game is played!
members will always find ways to benefit from situations
even if technically it may be illegal to do so, they will find
a way. My speculation is that Tang "knows" that AUPH
will be acquired by BP at a time and a price that will enrich
himself and the other board members. Even PG made a
comment at the conclusion of the strategic review that at
anytime a BP can make an offer for AUPH, even though
the strategic review process had ended. Maybe PG set
the bar to high for an official offer to be made at that time.
As of right now, it looks as if AUPH is more attractive than
it was in the past. Tang knows how the game is played!
Recent AUPH News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:31:08 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/13/2026 11:27:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:05:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:04:33 PM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 • Business Wire • 02/19/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:12:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:11:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2025 01:00:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/04/2025 11:06:12 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress • Business Wire • 11/04/2025 11:00:00 AM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 • Business Wire • 11/03/2025 11:00:00 AM
